SCHEMBL10159239

SCHEMBL10159239

O=C1CC(=O)N(CC(F)(F)Cc2ccc(Cl)c(Cl)c2)C(=O)N1CC(F)(F)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
HSP90B1 P14625 1/20 0.41
TRAP1 Q12931 1/20 0.41
FDPS P14324 1/20 0.39
MDH2 P40926 1/20 0.36
SIGMAR1 Q99720 4/20 0.36
MAPT P10636 4/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 2/20 0.35
USP2 O75604 2/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
APAF1 O14727 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18250148 0.93 KMT2A (0.39) KMT2AHSP90B1TRAP1FDPSMDH2
SCHEMBL10159321 0.84 MEN1 (0.37) KMT2ATRAP1MAPTPOLBMEN1
SCHEMBL10159337 0.82 KMT2A (0.45) KMT2ASIGMAR1MAPTPOLBMEN1
SCHEMBL10159238 0.82 MAPT (0.36) KMT2AMAPTPOLBMEN1USP2
SCHEMBL10159457 0.81 MEN1 (0.34) KMT2AMAPTPOLBMEN1USP2
SCHEMBL10159274 0.80 MAPT (0.42) KMT2AMAPTPOLBMEN1USP2
SCHEMBL18250149 0.78 ALDH1A1 (0.37) KMT2AMAPTPOLBMEN1SMN1; SMN2
SCHEMBL10195157 0.78 TRAP1 (0.42) KMT2ATRAP1MAPTPOLBMEN1
SCHEMBL10159199 0.78 TRAP1 (0.39) KMT2AHSP90B1TRAP1MDH2MAPT
SCHEMBL18250150 0.78 KMT2A (0.37) KMT2AMDH2MAPTPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 EP disclosed
US-9499494-B2 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2016-11-22 US disclosed
US-9499494-B2 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2016-11-22 US disclosed
EP-2427438-B1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS INC (US) 2016-10-12 EP disclosed
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2015-07-23 US disclosed
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2015-07-23 US disclosed
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NORTHWESTERN UNIVERSITY (US) 2012-02-23 US disclosed
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NORTHWESTERN UNIVERSITY (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 KMT2A 946/4885HSP90B1 4041/4885TRAP1 742/4885
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 KMT2A 946/4885HSP90B1 4041/4885TRAP1 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.